Compare ATNI & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATNI | BNR |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical Specialities |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 226.4M | 233.7M |
| IPO Year | 1991 | 2020 |
| Metric | ATNI | BNR |
|---|---|---|
| Price | $20.98 | $15.72 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 55.8K | ★ 63.8K |
| Earning Date | 11-05-2025 | 11-20-2025 |
| Dividend Yield | ★ 5.29% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $724,308,000.00 | $75,749,382.00 |
| Revenue This Year | $1.77 | $136.32 |
| Revenue Next Year | $2.06 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 5.56 |
| 52 Week Low | $13.76 | $2.18 |
| 52 Week High | $23.60 | $23.59 |
| Indicator | ATNI | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 64.97 | 48.27 |
| Support Level | $21.05 | $17.66 |
| Resistance Level | $21.99 | $23.59 |
| Average True Range (ATR) | 0.79 | 2.69 |
| MACD | -0.09 | -0.30 |
| Stochastic Oscillator | 59.41 | 17.85 |
ATN International Inc is a telecommunications and utilities company. The company provides digital infrastructure and communications services with a focus on rural and remote markets in the United States, and internationally, including Bermuda and the Caribbean region. Its operating segments comprise U.S. Telecom and International Telecom. The company earns revenue from its International telecommunication segment.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.